Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma

Journal of Thoracic and Cardiovascular Surgery

Volumn 144, Issue 6, 2012, Pages

  Li, Shau Hsuan ^a   Huang, Eng Yen ^a   Lu, Hung I ^a   Huang, Wan Ting ^a   Yen, Chueh Chuan ^b   Huang, Wen Chien ^c   Chen, Chang Han ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMINE DERIVATIVE; CISPLATIN; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84869081673     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.06.049     Document Type: Article

References (26)

1. J.R. Siewert, H.J. Stein, M. Feith, B.L. Bruecher, H. Bartels, and U. Fink Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world Ann Surg 234 2001 360 369
2. P.C. Lee, F.M. Mirza, J.L. Port, B.M. Stiles, S. Paul, and P. Christos Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma J Thorac Cardiovasc Surg 141 2011 1196 1206
3. M. Stahl, M. Stuschke, N. Lehmann, H.J. Meyer, M.K. Walz, and S. Seeber Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus J Clin Oncol 23 2005 2310 2317
4. L. Bedenne, P. Michel, O. Bouche, C. Milan, C. Mariette, and T. Conroy Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 J Clin Oncol 25 2007 1160 1168
5. K.L. Meredith, J.M. Weber, K.K. Turaga, E.M. Siegel, J. McLoughlin, and S. Hoffe Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer Ann Surg Oncol 17 2010 1159 1167
6. R.A. Meguid, C.M. Hooker, J.T. Taylor, L.R. Kleinberg, S.M. Cattaneo 2nd, and M.S. Sussman Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg 138 2009 1309 1317
7. A.C. Berger, J. Farma, W.J. Scott, G. Freedman, L. Weiner, and J.D. Cheng Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival J Clin Oncol 23 2005 4330 4337
8. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 2006 729 734
9. B.H. Jiang, and L.Z. Liu Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment Drug Resist Updat 11 2008 63 76
10. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. Esophagus and esophagogastric junction. In: AJCC Cancer Satging Manual. 7th ed. New York: Springer; 2010:103-11.
11. B.I. Rini Temsirolimus, an inhibitor of mammalian target of rapamycin Clin Cancer Res 14 2008 1286 1290
12. K. Hirashima, Y. Baba, M. Watanabe, R. Karashima, N. Sato, and Y. Imamura Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma Ann Surg Oncol 17 2010 2486 2493
13. Y. Dobashi, S. Suzuki, H. Matsubara, M. Kimura, S. Endo, and A. Ooi Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas Cancer 115 2009 107 118
14. Y. Dobashi, S. Suzuki, E. Sato, Y. Hamada, T. Yanagawa, and A. Ooi EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors Mod Pathol 22 2009 1328 1340
15. F. Xu, and Y.S. Zhen (-)-Epigallocatechin-3-gallate enhances anti-tumor effect of cytosine arabinoside on HL-60 cells Acta Pharmacol Sin 24 2003 163 168
16. W.C. Noh, Y.H. Kim, M.S. Kim, J.S. Koh, H.A. Kim, and N.M. Moon Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables Breast Cancer Res Treat 110 2008 477 483
17. S.M. Moore, R.C. Rintoul, T.R. Walker, E.R. Chilvers, C. Haslett, and T. Sethi The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway Cancer Res 58 1998 5239 5247
18. J.V. Reynolds, N. Ravi, D. Hollywood, M.J. Kennedy, S. Rowley, and A. Ryan Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy J Thorac Cardiovasc Surg 132 2006 549 555
19. F. Lefranc, V. Facchini, and R. Kiss Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas Oncologist 12 2007 1395 1403
20. I. Beuvink, A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, and T. O'Reilly The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation Cell 120 2005 747 759
21. O. Warburg On the origin of cancer cells Science 123 1956 309 314
22. Q. Sun, X. Chen, J. Ma, H. Peng, F. Wang, and X. Zha Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth Proc Natl Acad Sci U S A 108 2011 4129 4134
23. W.H. Mondesire, W. Jian, H. Zhang, J. Ensor, M.C. Hung, and G.B. Mills Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells Clin Cancer Res 10 2004 7031 7042
24. H. Itamochi, T. Oishi, M. Shimada, S. Sato, K. Uegaki, and J. Naniwa Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun Clin Cancer Res 17 2011 4742 4750
25. M. Wagner, V. Roh, M. Strehlen, A. Laemmle, D. Stroka, and B. Egger Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1 J Gastrointest Surg 13 2009 1781 1790
26. G. Hou, Q. Zhang, L. Wang, M. Liu, J. Wang, and L. Xue mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice Cancer Lett 290 2010 248 254